What it's for (Indications)
- Roxithromycin, a macrolide antibiotic, is indicated for the treatment of various bacterial infections caused by susceptible organisms.
- Its primary therapeutic uses encompass infections of the respiratory tract, including upper respiratory tract infections such as pharyngitis, tonsillitis, and sinusitis, as well as lower respiratory tract infections like acute bronchitis and community-acquired pneumonia.
- Furthermore, it is effective against certain skin and soft tissue infections, including conditions like folliculitis, furuncles, carbuncles, impetigo, pyoderma, and erysipelas.
- Roxithromycin also plays a role in managing specific genitourinary infections, notably non-gonococcal urethritis and cervicitis.
- The selection of roxithromycin should be guided by local epidemiological patterns of resistance and, whenever possible, by the results of susceptibility testing.
- It is often considered an alternative for patients who are allergic to penicillin or for infections caused by atypical pathogens where beta-lactams are less effective.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The typical adult dosage for roxithromycin is 150 mg administered orally twice daily, approximately every 12 hours, or 300 mg once daily, preferably before a meal to optimize absorption. The duration of treatment varies depending on the specific infection being treated and its severity, commonly ranging from 5 to 10 days. For instance, uncomplicated pharyngitis or tonsillitis may require 5-10 days, while more severe infections like pneumonia might necessitate a longer course. In patients with severe hepatic impairment, dosage adjustment is crucial, often recommending a reduction to half the usual daily dose, such as 150 mg once daily, to mitigate the risk of drug accumulation and potential hepatotoxicity. Dosage adjustments are generally not required for patients with renal impairment, unless the impairment is exceptionally severe and potentially combined with hepatic dysfunction. It is imperative that patients complete the entire prescribed course of therapy, even if symptoms improve, to ensure eradication of the infection and minimize the development of antibiotic resistance. |
Safety & Warnings
Common Side Effects
- Roxithromycin can induce a range of side effects, although their incidence and severity vary among individuals.
- The most commonly reported adverse reactions are gastrointestinal in nature, including nausea, vomiting, abdominal pain or cramps, and diarrhea.
- Other less frequent but notable side effects include headache, dizziness, fatigue, altered taste or smell perception (dysgeusia/anosmia), and skin reactions such such as rash, pruritus, or urticaria.
- More severe, albeit rare, adverse events include hypersensitivity reactions, which can manifest as anaphylaxis, angioedema, Stevens-Johnson syndrome (SJS), or toxic epidermal necrolysis (TEN).
- Hepatotoxicity, presenting as elevated liver enzymes, cholestatic hepatitis, or jaundice, has also been reported.
- Cardiovascular concerns such as QT interval prolongation and, in very rare instances, Torsades de Pointes, are potential risks, especially in predisposed individuals or with co-administration of certain medications.
- *Clostridioides difficile*-associated diarrhea (CDAD) is another serious potential complication that can occur during or after antibiotic treatment, ranging from mild to life-threatening pseudomembranous colitis.
Serious Warnings
- Black Box Warning: Roxithromycin does not carry a formal FDA Black Box Warning. However, considering its pharmacological profile and potential for serious adverse events, the following 'Serious Warnings' section provides critical safety information that healthcare professionals and patients should be acutely aware of during treatment: **Serious Warnings** **1. QT Prolongation and Cardiac Arrhythmias:** Roxithromycin has been associated with prolongation of the QTc interval on the electrocardiogram. This effect can be particularly pronounced in patients with pre-existing conditions that predispose to QT prolongation, such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or those receiving concomitant medications known to prolong the QTc interval. QT prolongation carries a rare but serious risk of developing Torsades de Pointes, a potentially fatal polymorphic ventricular tachycardia. Consequently, co-administration with other drugs known to significantly prolong the QT interval and which are substrates of CYP3A4, such as astemizole, cisapride, pimozide, and terfenadine, is strictly contraindicated. Careful assessment of cardiac risk factors is essential before initiating roxithromycin therapy. **2. Hepatotoxicity:** Cases of hepatic dysfunction, ranging from transient elevations in liver enzymes to severe cholestatic hepatitis and jaundice, have been reported during or following roxithromycin treatment. While often reversible upon discontinuation, severe cases can occur. Patients with pre-existing hepatic impairment are at an increased risk, and significant dose reduction or avoidance is recommended in severe cases. Liver function tests should be monitored if signs or symptoms of liver injury develop (e.g., jaundice, dark urine, persistent nausea/vomiting, abdominal pain). **3. *Clostridioides difficile*-Associated Diarrhea (CDAD):** *Clostridioides difficile*-associated diarrhea (CDAD) has been reported with the use of nearly all antibacterial agents, including roxithromycin, and can range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of *C. difficile*. This bacterium produces toxins A and B, which contribute to the development of CDAD. It is important to consider CDAD in all patients who present with diarrhea following antibiotic use, as it can occur over two months post-administration. Appropriate management, including fluid and electrolyte replacement, protein supplementation, and specific antibacterial treatment against *C. difficile*, should be initiated if suspected or confirmed. **4. Serious Hypersensitivity Reactions:** Severe acute hypersensitivity reactions, including anaphylaxis, angioedema, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), have been reported with macrolide antibiotics, including roxithromycin. If a severe hypersensitivity reaction occurs, roxithromycin should be discontinued immediately, and appropriate emergency medical treatment should be administered. **5. Drug Interactions:** Roxithromycin is a substrate and inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme. Co-administration with other drugs metabolized by or affecting CYP3A4 can lead to significant drug interactions, potentially altering plasma concentrations and increasing the risk of adverse effects of co-administered medications (e.g., warfarin, digoxin, midazolam, cyclosporine, and ergot alkaloids). Concurrent use with ergot alkaloids is contraindicated due to the risk of acute ergotism. A thorough review of a patient’s concomitant medications is crucial before and during roxithromycin therapy to prevent serious adverse drug interactions.
- Roxithromycin should be administered with caution in patients with conditions that predispose them to QT interval prolongation, including uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or concomitant use of other medications known to prolong the QT interval, given the potential risk for Torsades de Pointes.
- Liver function should be closely monitored in patients with pre-existing hepatic impairment or those who develop signs or symptoms of liver dysfunction during treatment, as severe hepatotoxicity, including cholestatic hepatitis, has been reported.
- The development of *Clostridioides difficile*-associated diarrhea (CDAD) is a significant risk with nearly all antibacterial agents, including roxithromycin, and can range in severity from mild diarrhea to fatal colitis; therefore, careful evaluation is necessary if diarrhea occurs during or after treatment.
- Caution is also advised in patients with myasthenia gravis, as macrolide antibiotics have been reported to exacerbate symptoms of this neuromuscular disorder.
- Prolonged or repeated use of roxithromycin may result in superinfection with non-susceptible bacteria or fungi, necessitating appropriate clinical management.
- Significant drug interactions, particularly involving the cytochrome P450 3A4 (CYP3A4) enzyme, require careful consideration, as roxithromycin can inhibit this enzyme, leading to increased plasma concentrations of co-administered drugs.
How it Works (Mechanism of Action)
Roxithromycin, belonging to the macrolide class of antibiotics, exerts its bacteriostatic effect primarily by inhibiting bacterial protein synthesis. It achieves this by binding reversibly to the 50S ribosomal subunit of susceptible bacteria. This binding action occurs at or near the peptidyl transferase center, interfering with the translocation step of protein synthesis. Specifically, roxithromycin prevents the movement of peptidyl-tRNA from the A (aminoacyl) site to the P (peptidyl) site of the ribosome, thereby inhibiting the elongation of the nascent polypeptide chain. This disruption effectively halts the production of essential bacterial proteins, which are vital for bacterial growth, replication, and overall survival. While generally considered bacteriostatic, meaning it inhibits bacterial growth, at higher concentrations or against highly susceptible pathogens, roxithromycin can exhibit bactericidal activity. Its spectrum of activity covers a range of Gram-positive bacteria, some Gram-negative bacteria, and atypical pathogens like Mycoplasma, Chlamydia, and Legionella species, making it suitable for treating various respiratory, skin, and sexually transmitted infections.
Commercial Brands (Alternatives)
No other brands found for this formula.